EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma

Johannes Lutz, Randi K Feist, Tim Sonntag, Esteban Peguero-Sánchez, Katharina Wolter, Ronja Bick, Jens Bauer, Juliane S Walz, Regina Heidenreich

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04178-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Johannes Lutz und 8 weiteren Autor:innen. Beteiligte Einrichtung: CureVac SE, Friedrich-Miescher-Strasse 15, 72076, Tübingen, Germany. Johannes.lutz@curevac.com. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, RNA, Messenger, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CureVac SE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM), an aggressive brain tumour associated with poor prognosis and high recurrence rate, has limited clinical treatment options. However, novel immunotherapeutics targeting over-presented epitopes of tumour-associated antigens (TAAs) represent a promising solution. Here we describe the preclinical development of CVGBM, an mRNA-based immunotherapeutic candidate for GBM consisting of a nucleotide-unmodified mRNA encapsulated in lipid nanoparticles (LNP). CVGBM mRNA encodes a fusion protein comprising eight TAA-derived epitopes that have previously induced T-cell responses in patients with GBM as peptide-based immunotherapeutics: five restricted to class I human leukocyte antigen (HLA) allele A*02:01 and three restricted to various class II HLA-DR alleles. Translation and processing of the mRNA-encoded fusion protein and presentation of derived epitopes on HLA molecules were confirmed in human cell lines after lipofection with CVGBM mRNA. Immunopeptidomics confirmed the presentation of four of the six HLA-A*02:01-restricted epitopes; however, HLA class II-bound epitopes were not detected. Administration of CVGBM to mice demonstrated functionality of the immunotherapeutic in vivo by inducing CD8 + and CD4 + T-cell responses. As CVGBM requires an intact immune system for its mode of action, it could not be tested in xenograft models. Instead, anti-tumoural efficacy was demonstrated for a surrogate mRNA-based immunotherapeutic, which has a similar mRNA and protein design as CVGBM but encodes a fusion protein comprising epitopes of the murine B16.F10 melanoma cell line. Administration of the surrogate immunotherapeutic prolonged median survival time of B16.F10 tumour-bearing mice relative to controls. Based on these results, a Phase I clinical trial with CVGBM was started in HLA-A*02:01-positive patients with surgically resected MGMT-unmethylated GBM (NCT05938387).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunotherapyRNA, MessengerBrain NeoplasmsAntigens, NeoplasmEpitopes, T-LymphocyteCancer VaccinesAnimalsHumansMiceCell Line, TumorNanoparticlesFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

Cancer vaccineGlioblastomaImmunotherapymRNA-based immunotherapeutic

Substanzen

RNA, MessengerAntigens, NeoplasmEpitopes, T-LymphocyteCancer Vaccines

Autor:innen und Institutionen

  • CureVac SE, Friedrich-Miescher-Strasse 15, 72076, Tübingen, Germany. Johannes.lutz@curevac.com.
  • CureVac SE, Friedrich-Miescher-Strasse 15, 72076, Tübingen, Germany.
  • Department of Peptide-Based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany.
  • Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • German Cancer Consortium (DKTK), Partner Site Tübingen, DKFZ and University Hospital Tübingen Partnership, Tübingen, Germany.
  • Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.

Förderung

  • CureVac SE

Zitieren

APA

Lutz, J., Feist, R. K., Sonntag, T., Peguero-Sánchez, E., Wolter, K., Bick, R., Bauer, J., Walz, J. S., & Heidenreich, R. (2025). Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04178-x

Vancouver

Lutz J, Feist RK, Sonntag T, Peguero-Sánchez E, Wolter K, Bick R, et al. Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04178-x

BibTeX
@article{Lutz2025,
  author = {Lutz, Johannes and Feist, Randi K and Sonntag, Tim and Peguero-Sánchez, Esteban and Wolter, Katharina and Bick, Ronja and Bauer, Jens and Walz, Juliane S and Heidenreich, Regina},
  title = {Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04178-x}
}
Kostenlos starten →